Asklepios Biopharmaceutical, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.askbio.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- Conditions
- Parkinson Disease
- Interventions
- Drug: AAV2-GDNF Gene therapyProcedure: Control Surgery
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- AskBio Inc
- Target Recruit Count
- 87
- Registration Number
- NCT06285643
- Locations
- 🇺🇸
UCI Alpha Clinic (Neurology), Irvine, California, United States
🇺🇸Loma Linda University (Neurology), Loma Linda, California, United States
🇺🇸Loma Linda University (Surgical), Loma Linda, California, United States
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
- Conditions
- Multiple System Atrophy, Parkinson VariantParkinson's DiseaseMultiple System Atrophy
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Asklepios Biopharmaceutical, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05699460
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AskBio Inc
- Target Recruit Count
- 150
- Registration Number
- NCT05598333
- Locations
- 🇺🇸
Cardiology P.C. Birmingham, Birmingham, Alabama, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Baycare Medical Group, Clearwater, Florida, United States
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
- Conditions
- Muscular DystrophyFukutin Related ProteinLimb-Girdle Muscular Dystrophy Type 2LGMD2LGMDFKRPFKRP MutationLimb Girdle Muscular DystrophyLGMD2I
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Asklepios Biopharmaceutical, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05230459
- Locations
- 🇺🇸
University of California - Irvine, Irvine, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
AB-1002 in Patients With Class III Heart Failure
- Conditions
- Congestive Heart FailureHeart Failure, DiastolicHeart; ComplicationsHeart Disease, IschemicHeart Failure, SystolicHeart FailureCardiovascular DiseasesHeart Failure，CongestiveHeart Arrhythmia
- Interventions
- Biological: 3 x 10e13vg AB-1002
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AskBio Inc
- Target Recruit Count
- 17
- Registration Number
- NCT04179643
- Locations
- 🇺🇸
Minneapolis Heart Foundation Institute, Minneapolis, Minnesota, United States
🇺🇸The Linder Center for Education and Research at The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
- Prev
- 1
- 2
- Next
News
AskBio's AB-1003 Receives FDA Rare Pediatric Disease and Orphan Drug Designations for LGMD2I/R9
AskBio's AB-1003 (LION-101) has been granted rare pediatric disease designation by the FDA for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).